Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire has formed a strategic alliance with Shionogi & Co to co-develop and co-market Shire's Attention Deficit Hyperactivity Disorder (ADHD) medicines in Japan.
Subscribe to our email newsletter
In exchange for rights to jointly co-develop and co- market the products, Shionogi will pay a one time fee and share costs to Shire.
Shire ADHD business senior vice president Mike Yasick said this agreement with Shionogi underscores their commitment to help patients diagnosed with ADHD.
"We look forward to work with the Shionogi team on efforts to enhance awareness in Japan about the impact undiagnosed and untreated ADHD can have on our societies, and the value that new treatment options can deliver for ADHD patients," Yasick said.